Olanexidine gluconate versus povidone-iodine for preventing surgical-site infection in orthopaedic surgery: A
Mitsuru Asukai1, Tsuyoshi Ohishi1, Tomotada Fujita1
1Department of Orthopaedic Surgery, Enshu Hospital, 1-1-1 Chuo, Naka-ku, Hamamatsu, Shizuoka 430-0929, Japan.
Background:
Olanexidine gluconate (OLG) is a newly developed skin antiseptic, which is effective against a broad range of bacteria, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus. The purpose of this study was to evaluate the bactericidal efficacy and safety of OLG in orthopaedic surgery.
Methods:
This retrospective study included a total of 1103 patients who underwent clean orthopaedic surgery. They were divided into two groups: 556 patients who were treated with OLG (OLG group), and 547 patients who were treated with povidone-iodine (PVP-I) (PVP-I group). The efficacy and the safety outcomes were measured as the rate of surgical-site infection (SSI) within 30 days after surgery and the rate of adverse skin reaction, respectively.
Results:
There was no significant difference between the OLG group and PVP-I group (1.80% vs. 2.38%; p = 0.50) based on the overall rate of SSI. Also, there was no significant difference in both superficial incisional infections (1.08% vs. 2.01%; p = 0.21) and deep incisional infections (0.72% vs. 0.37%; p = 0.35). The overall rate of adverse skin reaction was significantly higher in the OLG group than in the PVP-I group (2.16% vs. 0.73%; p = 0.047).
Conclusions:
This retrospective study demonstrated that OLG has an efficacy similar to PVP-I in preventing SSI in clean orthopaedic surgery. However, adverse skin reactions at the application site of OLG requires more attention.
Insights
Olanexidine gluconate (OLG) shows similar efficacy to povidone-iodine (PVP-I) in preventing surgical-site infections in orthopaedic surgery. However, OLG was associated with a higher rate of adverse skin reactions.
Area of Science:
- Infectious Disease
- Surgical Safety
- Dermatology
Background:
- Olanexidine gluconate (OLG) is a novel antiseptic with broad-spectrum antibacterial activity.
- It is effective against resistant bacteria like MRSA and VRE.
- OLG's potential in orthopaedic surgery required evaluation.
Purpose of the Study:
- To compare the efficacy of OLG versus povidone-iodine (PVP-I) in preventing surgical-site infections (SSI).
- To assess the safety profile, specifically adverse skin reactions, of OLG in orthopaedic patients.
Main Methods:
- Retrospective study of 1103 patients undergoing clean orthopaedic surgery.
- Patients were divided into OLG group (n=556) and PVP-I group (n=547).
- Outcomes measured: SSI rates within 30 days and adverse skin reactions.
Main Results:
- No significant difference in overall SSI rates between OLG (1.80%) and PVP-I (2.38%) groups (p=0.50).
- Superficial and deep incisional infection rates were also similar between groups.
- Adverse skin reactions were significantly higher in the OLG group (2.16%) compared to the PVP-I group (0.73%) (p=0.047).
Conclusions:
- OLG demonstrates comparable efficacy to PVP-I in preventing SSIs in clean orthopaedic procedures.
- The increased incidence of adverse skin reactions with OLG warrants careful consideration.
- Further investigation into managing OLG-associated skin reactions may be necessary.
More Related Videos
Related Concept Videos
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Cancer Prevention
Some...
Electrophilic Aromatic Substitution: Fluorination and Iodination of Benzene
Prevention of Further Absorption of Poison
Preventive Healthcare Services


